Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Assets (2017 - 2025)

Protagonist Therapeutics' Current Assets history spans 9 years, with the latest figure at $577.6 million for Q4 2025.

  • For Q4 2025, Current Assets fell 2.38% year-over-year to $577.6 million; the TTM value through Dec 2025 reached $577.6 million, down 2.38%, while the annual FY2025 figure was $577.6 million, 2.38% down from the prior year.
  • Current Assets for Q4 2025 was $577.6 million at Protagonist Therapeutics, down from $586.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $627.6 million in Q1 2024 and bottomed at $235.7 million in Q1 2023.
  • The 5-year median for Current Assets is $348.5 million (2022), against an average of $418.2 million.
  • The largest annual shift saw Current Assets tumbled 30.97% in 2023 before it skyrocketed 166.21% in 2024.
  • A 5-year view of Current Assets shows it stood at $340.7 million in 2021, then decreased by 28.66% to $243.1 million in 2022, then soared by 46.28% to $355.6 million in 2023, then skyrocketed by 66.39% to $591.6 million in 2024, then dropped by 2.38% to $577.6 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Current Assets are $577.6 million (Q4 2025), $586.4 million (Q3 2025), and $602.5 million (Q2 2025).